We are live on ! Find out more
AMRI

Albany Molecular Research Inc
AMRI

Delisted

AMRI was delisted on the 31st of August, 2017.

118 hedge funds and large institutions have $264M invested in Albany Molecular Research Inc in 2013 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 51 increasing their positions, 28 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

167% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 9

82% more repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 28

15% more funds holding

Funds holding: 103118 (+15)

13% more call options, than puts

Call options by funds: $1.43M | Put options by funds: $1.26M

2% less capital invested

Capital invested by funds: $269M → $264M (-$4.3M)

Holders
118
Holders Change
+15
Holders Change %
+14.56%
% of All Funds
3.43%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
24
Increased
51
Reduced
28
Closed
9
Calls
$1.43M
Puts
$1.26M
Net Calls
+$169K
Net Calls Change
+$101K
Name Holding Trade Value Shares
Change
Change in
Stake
HIM
101
Hillsdale Investment Management
Ontario, Canada
$57K -$253K -20,950 -79%
AllianceBernstein
102
AllianceBernstein
Tennessee
$41K -$88.1K -7,293 -64%
Barclays
103
Barclays
United Kingdom
$36K -$14.6K -1,206 -25%
TRCT
104
Tower Research Capital (TRC)
New York
$34K +$5.14K +425 +14%
First Manhattan
105
First Manhattan
New York
$30K
U
106
UBS
Switzerland
$22K +$20.4K +1,686 +337%
SGAM
107
Smith Group Asset Management
Texas
$21K
BPBT
108
Boston Private Bank & Trust
Massachusetts
$19K +$22.4K +1,855 New
BlackRock
109
BlackRock
New York
$6K
HF
110
Hoxton Financial
West Virginia
$5K +$5.23K +433 +541%
FWM
111
Focused Wealth Management
New York
$5K +$6.28K +520 New
BNP Paribas Financial Markets
112
BNP Paribas Financial Markets
France
$3.03K +$3.64K +301 New
Ameriprise
113
Ameriprise
Minnesota
$2K -$19.6K -1,620 -88%
GC
114
Globeflex Capital
California
$2K
Wells Fargo
115
Wells Fargo
California
$1K -$400K -33,099 -100%
Walleye Trading
116
Walleye Trading
New York
$1K +$665 +55 New
Manulife (Manufacturers Life Insurance)
117
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$188 +$14.3K +1,185 +7%
DIA
118
Denver Investment Advisors
Colorado
$114
Fuller & Thaler Asset Management
119
Fuller & Thaler Asset Management
California
-$4.57M -354,350 Closed
BIM
120
Bogle Investment Management
Massachusetts
-$3.6M -279,630 Closed
EI
121
EAM Investors
California
-$2.48M -192,125 Closed
TCM
122
Timpani Capital Management
Wisconsin
-$1.31M -101,542 Closed
HCM
123
Highbridge Capital Management
New York
-$408K -31,622 Closed
CA
124
Cetera Advisors
Colorado
-$172K -13,255 Closed
BG
125
BlackRock Group
United Kingdom
-$142K -10,991 Closed

AMRI Hedge Fund Activity: Q4 2013 in Review

118 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Albany Molecular Research Inc (AMRI) for Q4 2013, worth a combined $264M — down 1.6% from $269M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new AMRI positions and 9 closed out — a net gain of 15 holders — while 51 added to existing stakes and 28 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $28.4M. The largest seller was Fuller & Thaler Asset Management, exiting entirely with an estimated $4.57M sold.

  • 118 institutional investors held Albany Molecular Research Inc (AMRI) as of Q4 2013, up from 103 in Q3 2013.
  • Funds reported $264M of Albany Molecular Research Inc stock for Q4 2013, down 1.6% quarter-over-quarter.
  • 24 funds opened new Albany Molecular Research Inc positions in Q4 2013 and 9 closed out, a net change of +15 holders.
  • The largest Albany Molecular Research Inc buyer in Q4 2013 was Wellington Management Group, an estimated $28.4M added.
  • The largest Albany Molecular Research Inc seller in Q4 2013 was Fuller & Thaler Asset Management, an estimated $4.57M sold.

Based on aggregated 13F filings for Q4 2013.